ロード中...
All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors could effectively reduce HbA(1C) and postprandial hyperglycemia and could incur only minimal danger of hypoglycemia. Patients with uncontrolled diabetes might be treated by the complementary action of insulin plus DPP-4 inhibitors. Here, we compa...
保存先:
| 出版年: | BMC Endocr Disord |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6321656/ https://ncbi.nlm.nih.gov/pubmed/30611254 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12902-018-0330-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|